New Market Report: MediPoint: Viscosupplementation - Global Analysis and Market Forecasts

Osteoarthritis (OA) constitutes a growing public health burden, and is the most common cause of musculoskeletal disability across the globe. Intra-articular viscosupplementation with hyaluronic acid (HA) has become an increasingly accepted therapeutic alternative to knee replacement surgery in the symptomatic management of OA over the past decade. Going forward, palliative pain treatments are likely to continue to fare well as healthcare reform kicks in and lag times for knee replacement become the norm. Growth of the viscosupplementation market will be highest in the US and the Asia-Pacific (APAC) region, where there is a significant pent-up demand for early intervention in the management of OA.

The increasing prevalence of OA and the lower cost of prescribing viscosupplementation compared with knee replacement surgery have prompted the medical community to take a closer look at this therapy. However, there is a growing concern among physicians that the updated American Academy of Orthopaedic Surgeons (AAOS) and Osteoarthritis Research Society International (OARSI) treatment guidelines for knee OA will result in increased insurance denials for viscosupplementation. Moving forward, industry consolidation and intense competition in the viscosupplementation arena will cause increasing numbers of companies to augment their research efforts to differentiate their products from the lower-end competitors. The motivation to incorporate the favorable properties of different agents into a more effective viscosupplementation product has led to the manipulation and development of next-generation HA formulations consisting of not only HAs, but also pharmaceuticals, such as corticosteroids.

Full Report Details at
- http://www.fastmr.com/prod/1052803_medipoint.aspx?afid=301

Highlights

Key Questions Answered

* Future growth in the viscosupplementation market lies in the one-injection segment. What are the current adoption trends in different geographies? How will one-injection segment drive the market revenue growth in the upcoming years?
* In the US, some commercial insurers have completely excluded viscosupplementation treatment from their coverage. Even when the criteria for coverage have clearly been met by the patient, denials are common. Has this impacted the procedure volume growth in the US viscosupplementation market?
* Reimbursement is the single greatest barrier to the market growth for viscosupplementation procedures. How does the current payer mix look like in different countries?
* In recent years, there has been an expansion in the use of intra-articular HA viscosupplementation for treating OA at hips, shoulders, and other small joints. What are the current adoption trends in different regions?

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- MediPoint: Coronary Stents - SA Analysis and Market Forecasts
- MediPoint: Coronary Stents - US Analysis and Market Forecasts
- MediPoint: Coronary Stents - APAC Analysis and Market Forecasts
- MediPoint: Coronary Stents - EU Analysis and Market Forecasts
- MediPoint: Prosthetic Heart Valves - Global Analysis and Market Forecasts